Table 2.
Baseline characteristics between non CA-AKI group and CA-AKI group
| Non CA-AKI | CA-AKI | p Value | |
|---|---|---|---|
| N = 1150 | N = 158 | ||
| Demographics | |||
| Age, years | 79.0 53.49 | 79.70 4.06 | 0.121 |
| Sex, female, n (%) | 311 (27.0%) | 55 (34.8%) | 0.052 |
| Systolic blood pressure, mmHg | 135.96 22.21 | 131.64 25.47 | 0.078 |
| Diastolic blood pressure, mmHg | 71.66 19.93 | 71.03 13.88 | 0.723 |
| Hypertension, n (%) | 877 (76.3%) | 126 (79.8%) | 0.384 |
| Emergency PCI, n(%) | 153 (13.3%) | 49 (31.0%) | < 0.001 |
| Diabetes, n (%) | 590 (51.3%) | 109 (69.0%) | < 0.001 |
| Atrial fibrillation, n (%) | 142 (12.4%) | 34 (21.5%) | 0.002 |
| Smoker, n (%) | 352 (34.0%) | 44 (30.4%) | 0.430 |
| MI, n (%) | 455 (39.6%) | 107 (67.7%) | < 0.001 |
| Perioperative hypotension, n (%) | 96 (8.3%) | 43 (27.2%) | < 0.001 |
| Medical therapy during hospitalization | |||
| Statin, n (%) | 1132 (98.4%) | 156 (98.7%) | 1.000 |
| Antiplatelet agents, n (%) | 1129 (98.3%) | 153 (96.8%) | 0.231 |
| ACEI/ARB, n (%) | 931 (81.0%) | 123 (77.9%) | 0.413 |
| Metformin, n (%) | 150 (13.0%) | 21 (13.3%) | 1.000 |
| Laboratory measurements | |||
| Serum creatinine, μmol/L | 88.09 29.88 | 95.27 69.28 | 0.597 |
| WBC, × 109/L | 7.39 2.48 | 8.72 3.42 | < 0.001 |
| Lymphocyte, × 109/L | 1.70 0.64 | 1.54 0.69 | 0.005 |
| HGB, g/L | 129.96 16.06 | 126.71 19.03 | 0.099 |
| HCT | 0.38 0.05 | 0.37 0.05 | 0.073 |
| ALB, g/L | 39.78 4.15 | 37.57 4.21 | < 0.001 |
| Cholesterol, mg/dL | 159.85 43.50 | 161.98 38.06 | 0.187 |
| Glucose, mmol/L | 7.17 3.07 | 8.38 4.01 | < 0.001 |
| eGFR, mL/min/1.73 m2 | 78.93 23.75 | 78.47 34.06 | 0.247 |
| eGFR < 60 mL/min/1.73 m2, n (%) | 242(21.0%) | 45 (28.5%) | 0.044 |
| Urine PH | 6.29 0.72 | 6.22 0.80 | 0.090 |
| CONUT score | < 0.001 | ||
| 0–1, n (%) | 453 (39.4%) | 55 (34.8%) | |
| 2–4, n (%) | 630 (54.8%) | 78 (49.4%) | |
| ≥ 5, n (%) | 67 (5.8%) | 25 (15.8%) | |
| Anemia, n (%) | 267 (23.2%) | 48 (30.4%) | 0.061 |
| Hyperuricemia, n(%) | 395 (34.4%) | 77 (48.7%) | 0.001 |
| Procedure characteristic | |||
| Contrast volume, mL | 176.14 55.91 | 188.23 51.01 | 0.006 |
| Contrast volume ≥ 200 mL, n (%) | 190 (16.5%) | 45 (28.5%) | 0.003 |
| Iso-osmolar contrast media use, n (%) | 416 (36.2%) | 57 (36.1%) | 1.000 |
| Number of stents, n (%) | 1.65 0.78 | 1.58 0.73 | 0.388 |
| Multi-vessel coronary artery disease, n (%) | 915 (79.57%) | 135 (85.44%) | 0.102 |
MI myocardial infarction, PCI percutaneous coronary intervention, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, eGFR estimated glomerular filtration rate, ALB albumin, WBC white blood cell, HGB hemoglobin, HCT hematocrit